- TheStreet.com•13 minutes ago
Leerink analysts noted Amgen's (AMGN) better-than-expected 2016 third-quarter results yesterday but said the 'most important' disclosure is the 'apparent ending' of its Enbrel drug's pricing power.
- Motley Fool•14 minutes ago
Despite trouncing Wall Street once more with its third-quarter results, Amgen finds pricing woes for its lead drug take precedence.
- Associated Press•35 minutes ago
NEW YORK (AP) — U.S. stocks gave up much of an early gain Friday afternoon after the FBI notified Congress that it will investigate new emails linked to Democratic presidential candidate Hillary Clinton. That injected a note of uncertainty just a week and a half before the presidential election.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||144.86 x 100|
|Ask||144.90 x 200|
|Day's Range||142.64 - 151.76|
|52wk Range||139.02 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||14.82|
|Avg Vol (3m)||2,785,132|
|Dividend & Yield||4.00 (2.52%)|